[1] |
BLACK C J, FORD A C. Global burden of irritable bowel syndrome:trends,predictions and risk factors[J]. Nat Rev Gastroenterol Hepatol, 2020, 17(8):473-486. DOI: 10.1038/s41575-020-0286-8.
|
[2] |
张声生,汪红兵,李振华,等. 360例腹泻型肠易激综合征的聚类分析及证候特征研究[J]. 中华中医药杂志,2010,25(8):1183-1187.
|
[3] |
|
[4] |
CHEY W D, KURLANDER J, ESWARAN S. Irritable bowel syndrome:a clinical review[J]. JAMA, 2015, 313(9):949-958. DOI: 10.1001/jama.2015.0954.
|
[5] |
MUJAGIC Z, JONKERS D M A E, HUNGIN A P S,et al. Use of Rome criteria for the diagnosis of irritable bowel syndrome in primary care:a survey among European countries[J]. Eur J Gastroenterol Hepatol, 2017, 29(6):651-656. DOI: 10.1097/MEG.0000000000000848.
|
[6] |
|
[7] |
ZHANG Y, QIN G, LIU D R,et al. Increased expression of brain-derived neurotrophic factor is correlated with visceral hypersensitivity in patients with diarrhea-predominant irritable bowel syndrome[J]. World J Gastroenterol, 2019, 25(2):269-281. DOI: 10.3748/wjg.v25.i2.269.
|
[8] |
FAN F, TANG Y, DAI H F,et al. Blockade of BDNF signalling attenuates chronic visceral hypersensitivity in an IBS-like rat model[J]. Eur J Pain, 2020, 24(4):839-850. DOI: 10.1002/ejp.1534.
|
[9] |
MOAYYEDI P, ANDREWS C N, MACQUEEN G,et al. Canadian association of gastroenterology clinical practice guideline for the management of irritable bowel syndrome (IBS)[J]. J Can Assoc Gastroenterol, 2019, 2(1):6-29. DOI: 10.1093/jcag/gwy071.
|
[10] |
HÄUSER W, MARSCHALL U, LAYER P,et al. The prevalence,comorbidity,management and costs of irritable bowel syndrome[J]. Dtsch Arztebl Int, 2019, 116(27/28):463-470. DOI: 10.3238/arztebl.2019.0463.
|
[11] |
HU X G, XU D, ZHAO Y,et al. The alleviating pain effect of aqueous extract from Tong-Xie-Yao-fang,on experimental visceral hypersensitivity and its mechanism[J]. Biol Pharm Bull, 2009, 32(6):1075-1079. DOI: 10.1248/bpb.32.1075.
|
[12] |
|
[13] |
GRACIE D J, HAMLIN P J, FORD A C. The influence of the brain-gut axis in inflammatory bowel disease and possible implications for treatment[J]. Lancet Gastroenterol Hepatol, 2019, 4(8):632-642. DOI: 10.1016/S2468-1253(19)30089-5.
|
[14] |
YIN Y, ZHONG L, WANG J W,et al. Tong Xie Yao Fang relieves irritable bowel syndrome in rats via mechanisms involving regulation of 5-hydroxytryptamine and substance P[J]. World J Gastroenterol, 2015, 21(15):4536-4546. DOI: 10.3748/wjg.v21.i15.4536.
|
[15] |
LIN Y J,DING Y,LÜ B,et al. Effect of Tongxieyaofang Decoction on colonic mucosal protein expression profiles in rats with visceral hypersensitivity[J]. Chung I Tsa Chih Ying Wen Pan,2020,40(2):245-252.
|
[16] |
HOU Q K, HUANG Y Q, ZHU Z Y,et al. Tong-Xie-Yao-Fang improves intestinal permeability in diarrhoea-predominant irritable bowel syndrome rats by inhibiting the NF-κB and Notch signalling pathways[J]. BMC Complement Altern Med, 2019, 19(1):337. DOI: 10.1186/s12906-019-2749-4.
|
[17] |
|
[18] |
CHEN M, TANG T C, WANG Y,et al. Randomised clinical trial:Tong-Xie-Yao-Fang granules versus placebo for patients with diarrhoea-predominant irritable bowel syndrome[J]. Aliment Pharmacol Ther, 2018, 48(2):160-168. DOI: 10.1111/apt.14817.
|
[19] |
JIN D Y, LIU Y N, LV S Y,et al. Electroacupuncture and moxibustion modulate the BDNF and TrkB expression in the colon and dorsal root Ganglia of IBS rats with visceral hypersensitivity[J]. Evid Based Complement Alternat Med, 2021, 2021:8137244. DOI: 10.1155/2021/8137244.
|
[20] |
|
[21] |
|
[22] |
魏伟,吴希美,李元建. 药理实验方法学[M]. 4版. 北京:人民卫生出版社,2010.
|
[23] |
LEWIS S J, HEATON K W. Stool form scale as a useful guide to intestinal transit time[J]. Scand J Gastroenterol, 1997, 32(9):920-924. DOI: 10.3109/00365529709011203.
|
[24] |
ZHAO Y, JIANG H L, SHI Y,et al. Electroacupuncture alleviates visceral hypersensitivity in IBS-D rats by inhibiting EGCs activity through regulating BDNF/TrkB signaling pathway[J]. Evid Based Complement Alternat Med, 2022, 2022:2497430. DOI: 10.1155/2022/2497430.
|
[25] |
MOLONEY R D, DINAN T G, CRYAN J F. Strain-dependent variations in visceral sensitivity:relationship to stress,anxiety and spinal glutamate transporter expression[J]. Genes Brain Behav, 2015, 14(4):319-329. DOI: 10.1111/gbb.12216.
|
[26] |
ZHAO C, LIN M J, PAN Y S,et al. Blockage of high-affinity choline transporter increases visceral hypersensitivity in rats with chronic stress[J]. Gastroenterol Res Pract, 2018, 2018:9252984. DOI: 10.1155/2018/9252984.
|
[27] |
KOWIANSKI P, LIETZAU G, CZUBA E,et al. BDNF:a key factor with multipotent impact on brain signaling and synaptic plasticity[J]. Cell Mol Neurobiol, 2018, 38(3):579-593. DOI: 10.1007/s10571-017-0510-4.
|
[28] |
CAPPOLI N, TABOLACCI E, ACETO P,et al. The emerging role of the BDNF-TrkB signaling pathway in the modulation of pain perception[J]. J Neuroimmunol, 2020, 349:577406. DOI: 10.1016/j.jneuroim.2020.577406.
|
[29] |
ZHANG Y, BI Y X, CHEN J,et al. Association of Peroxiredoxin 1 and brain-derived neurotrophic factor serum levels with depression and anxiety symptoms in patients with irritable bowel syndrome[J]. Gen Hosp Psychiatry, 2021, 68:59-64. DOI: 10.1016/j.genhosppsych.2020.11.010.
|
[30] |
KONTUREK T J, MARTINEZ C, NIESLER B,et al. The role of brain-derived neurotrophic factor in irritable bowel syndrome[J]. Front Psychiatry, 2020, 11:531385. DOI: 10.3389/fpsyt.2020.531385.
|
[31] |
|
[32] |
|
[33] |
旺建伟,叶虹玉,殷越,等. 痛泻要方对肠易激综合征内脏高敏性大鼠结肠组织肥大细胞活化、P物质表达及相关性的影响[J]. 中华中医药杂志,2014,29(6):1982-1986.
|
[34] |
HARRIS J A, FAUST B, GONDIN A B,et al. Selective G protein signaling driven by substance P-neurokinin receptor dynamics[J]. Nat Chem Biol, 2022, 18(1):109-115. DOI: 10.1038/s41589-021-00890-8.
|
[35] |
IFTIKHAR K, SIDDIQ A, BAIG S G,et al. Substance P:a neuropeptide involved in the psychopathology of anxiety disorders[J]. Neuropeptides, 2020, 79:101993. DOI: 10.1016/j.npep.2019.101993.
|
[36] |
|
[37] |
PAN F, ZHANG T, ZHANG Y H,et al. Effect of Tongxie Yaofang Granule in treating diarrhea-predominate irritable bowel syndrome[J]. Chin J Integr Med, 2009, 15(3):216-219. DOI: 10.1007/s11655-009-0216-7.
|